Mark Breidenbach
Stock Analyst at Oppenheimer
(1.72)
# 3,387
Out of 5,152 analysts
48
Total ratings
30.91%
Success rate
1.83%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Breidenbach
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALLO Allogene Therapeutics | Maintains: Outperform | $9 → $7 | $2.31 | +203.03% | 6 | Aug 1, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Outperform | $27 → $30 | $15.22 | +97.11% | 4 | Sep 4, 2024 | |
| ARVN Arvinas | Reiterates: Outperform | $95 | $13.72 | +592.42% | 6 | Aug 9, 2023 | |
| IMRX Immuneering | Reiterates: Outperform | $25 | $4.98 | +402.01% | 3 | Aug 8, 2023 | |
| CUE Cue Biopharma | Assumes: Outperform | $10 | $0.29 | +3,374.64% | 6 | Jun 26, 2023 | |
| MCRB Seres Therapeutics | Assumes: Outperform | $240 | $9.52 | +2,421.01% | 4 | Jun 26, 2023 | |
| BLRX BioLineRx | Reiterates: Outperform | $160 | $2.71 | +5,804.06% | 1 | May 25, 2023 | |
| CGEN Compugen | Maintains: Outperform | $8 → $7 | $2.05 | +241.46% | 7 | May 16, 2023 | |
| CRBU Caribou Biosciences | Maintains: Outperform | $36 → $32 | $1.71 | +1,771.35% | 2 | Mar 10, 2023 | |
| IOVA Iovance Biotherapeutics | Maintains: Outperform | $25 → $15 | $4.58 | +227.51% | 7 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11,250 → $9,750 | $0.95 | +1,026,972.58% | 2 | May 12, 2020 |
Allogene Therapeutics
Aug 1, 2025
Maintains: Outperform
Price Target: $9 → $7
Current: $2.31
Upside: +203.03%
Nurix Therapeutics
Sep 4, 2024
Maintains: Outperform
Price Target: $27 → $30
Current: $15.22
Upside: +97.11%
Arvinas
Aug 9, 2023
Reiterates: Outperform
Price Target: $95
Current: $13.72
Upside: +592.42%
Immuneering
Aug 8, 2023
Reiterates: Outperform
Price Target: $25
Current: $4.98
Upside: +402.01%
Cue Biopharma
Jun 26, 2023
Assumes: Outperform
Price Target: $10
Current: $0.29
Upside: +3,374.64%
Seres Therapeutics
Jun 26, 2023
Assumes: Outperform
Price Target: $240
Current: $9.52
Upside: +2,421.01%
BioLineRx
May 25, 2023
Reiterates: Outperform
Price Target: $160
Current: $2.71
Upside: +5,804.06%
Compugen
May 16, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $2.05
Upside: +241.46%
Caribou Biosciences
Mar 10, 2023
Maintains: Outperform
Price Target: $36 → $32
Current: $1.71
Upside: +1,771.35%
Iovance Biotherapeutics
Mar 1, 2023
Maintains: Outperform
Price Target: $25 → $15
Current: $4.58
Upside: +227.51%
May 12, 2020
Maintains: Outperform
Price Target: $11,250 → $9,750
Current: $0.95
Upside: +1,026,972.58%